Japan’s Teijin Parma has entered into an exclusive global license agreement with Swiss pharma giant Novartis (NOVN: VX) to research, develop, manufacture and commercialize an investigational pre-clinical candidate for proteinuric kidney diseases.
The investigational small molecule candidate was discovered at the Teijin Institute for Bio-medical Research, Teijin’s drug development base in Tokyo. The candidate acts in a genetically validated pathway and is believed to impact the pathogenesis of multiple kidney diseases.
This deal comes about since Novartis made the decision to divest its clinical non-alcoholic steatohepatitis (NASH) assets as part of its new strategy focusing on five core therapeutic segments: cardiovascular, hematology, solid tumors, immunology and neuroscience. Novartis last month announced it was pulling out of a NASH collaboration with US biotech Pliant Therapeutics (Nasdaq: PLRX).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze